{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:02:44Z","timestamp":1775041364156,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.7759\/cureus.106256","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:11:27Z","timestamp":1775034687000},"source":"Crossref","is-referenced-by-count":0,"title":["Correlation of Histopathological Parameters With Molecular Markers in Carcinoma Endometrium"],"prefix":"10.7759","author":[{"given":"Kanika B","family":"Modi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shefali","family":"Sardana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Batra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harit","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Indian Council of Medical Research. Report of National Cancer Registry Programme, 2020. (2020). Accessed. March 28, 2026: https:\/\/ncdirindia.org\/All_Reports\/Report_2020\/Brf_2020\/NCRPReport2020_Brief_write_up.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5468\/ogs.22053","article-title":"Endometrial thickness and uterine artery Doppler parameters as soft markers for prediction of endometrial cancer in postmenopausal bleeding women: a cross-sectional study at tertiary referral hospitals from Vietnam","volume":"65","author":"Nguyen PN","year":"2022","unstructured":"Nguyen PN, Nguyen VT. Endometrial thickness and uterine artery Doppler parameters as soft markers for prediction of endometrial cancer in postmenopausal bleeding women: a cross-sectional study at tertiary referral hospitals from Vietnam. Obstet Gynecol Sci. 2022, 65:430-40. 10.5468\/ogs.22053","journal-title":"Obstet Gynecol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40477-022-00732-w","article-title":"Additional value of Doppler ultrasound to B-mode ultrasound in assessing for uterine intracavitary pathologies among perimenopausal and postmenopausal bleeding women: a multicentre prospective observational study in Vietnam","volume":"26","author":"Nguyen PN","year":"2023","unstructured":"Nguyen PN, Nguyen VT. Additional value of Doppler ultrasound to B-mode ultrasound in assessing for uterine intracavitary pathologies among perimenopausal and postmenopausal bleeding women: a multicentre prospective observational study in Vietnam. J Ultrasound. 2023, 26:459-69. 10.1007\/s40477-022-00732-w","journal-title":"J Ultrasound"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth C","year":"2013","unstructured":"Kandoth C, Schultz N, Cherniack AD, et al.. Integrated genomic characterization of endometrial carcinoma. Nature. 2013, 497:67-73. 10.1038\/nature12113","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma","volume":"478","author":"Concin N","year":"2021","unstructured":"Concin N, Creutzberg CL, Vergote I, et al.. ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch. 2021, 478:153-90. 10.1007\/s00428-020-03007-z","journal-title":"Virchows Arch"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk A","year":"2015","unstructured":"Talhouk A, McConechy MK, Leung S, et al.. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015, 113:299-310. 10.1038\/bjc.2015.190","journal-title":"Br J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.7066","article-title":"Evolving roles of histologic evaluation and molecular\/genomic profiling in the management of endometrial cancer","volume":"16","author":"Murali R","year":"2018","unstructured":"Murali R, Delair DF, Bean SM, Abu-Rustum NR, Soslow RA. Evolving roles of histologic evaluation and molecular\/genomic profiling in the management of endometrial cancer. J Natl Compr Canc Netw. 2018, 16:201-9. 10.6004\/jnccn.2017.7066","journal-title":"J Natl Compr Canc Netw"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-025-00145-2","article-title":"Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification","volume":"3","author":"Yoshimura T","year":"2025","unstructured":"Yoshimura T, Nakamura K, Chiyoda T, et al.. Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification. BJC Rep. 2025, 3:37. 10.1038\/s44276-025-00145-2","journal-title":"BJC Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-020-00811-5","article-title":"Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer","volume":"26","author":"Raffone A","year":"2020","unstructured":"Raffone A, Travaglino A, Cerbone M, Gencarelli A, Mollo A, Insabato L, Zullo F. Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res. 2020, 26:1417-27. 10.1007\/s12253-020-00811-5","journal-title":"Pathol Oncol Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153025","article-title":"Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer","volume":"216","author":"Raffone A","year":"2020","unstructured":"Raffone A, Travaglino A, Cerbone M, et al.. Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer. Pathol Res Pract. 2020, 216:153025. 10.1016\/j.prp.2020.153025","journal-title":"Pathol Res Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.008","article-title":"Histopathological characterization of ProMisE molecular groups of endometrial cancer","volume":"157","author":"Raffone A","year":"2020","unstructured":"Raffone A, Travaglino A, Mascolo M, et al.. Histopathological characterization of ProMisE molecular groups of endometrial cancer. Gynecol Oncol. 2020, 157:252-9. 10.1016\/j.ygyno.2020.01.008","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.08.001","article-title":"Precision medicine in endometrial cancer","volume":"154","author":"McAlpine JN","year":"2019","unstructured":"McAlpine JN, Gilks CB. Precision medicine in endometrial cancer. Gynecol Oncol. 2019, 154:451-3. 10.1016\/j.ygyno.2019.08.001","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101869","article-title":"Endometrial cancer: 2023 revised FIGO staging system and the role of imaging","volume":"16","author":"Menendez-Santos M","year":"2024","unstructured":"Menendez-Santos M, Gonzalez-Baerga C, Taher D, Waters R, Virarkar M, Bhosale P. Endometrial cancer: 2023 revised FIGO staging system and the role of imaging. Cancers (Basel). 2024, 16:1869. 10.3390\/cancers16101869","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030651","article-title":"Clinicopathologic vs. molecular integrated prognostication of endometrial carcinoma by European guidelines","volume":"14","author":"Loukovaara M","year":"2022","unstructured":"Loukovaara M, Pasanen A, B\u00fctzow R. Clinicopathologic vs. molecular integrated prognostication of endometrial carcinoma by European guidelines. Cancers (Basel). 2022, 14:651. 10.3390\/cancers14030651","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-024-01584-0","article-title":"Prognostic factors and survival outcomes of immunohistochemically detection based-molecular subtypes of endometrial cancer-analysis of 576 clinical cases","volume":"19","author":"Wang X","year":"2024","unstructured":"Wang X, Aziz AU, Wang D, Wang Y, Liu M, Yu X, Wang D. Prognostic factors and survival outcomes of immunohistochemically detection based-molecular subtypes of endometrial cancer-analysis of 576 clinical cases. Diagn Pathol. 2024, 19:162. 10.1186\/s13000-024-01584-0","journal-title":"Diagn Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility","volume":"38 Suppl 1","author":"K\u00f6bel M","year":"2019","unstructured":"K\u00f6bel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol. 2019, 38 Suppl 1:S123-31. 10.1097\/PGP.0000000000000488","journal-title":"Int J Gynecol Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.02.006","article-title":"Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier","volume":"111","author":"Huvila J","year":"2021","unstructured":"Huvila J, Orte K, Vainio P, Mett\u00e4l\u00e4 T, Joutsiniemi T, Hietanen S. Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier. Hum Pathol. 2021, 111:98-109. 10.1016\/j.humpath.2021.02.006","journal-title":"Hum Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss S","year":"2018","unstructured":"Kommoss S, McConechy MK, Kommoss F, et al.. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018, 29:1180-8. 10.1093\/annonc\/mdy058","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153783","article-title":"The role of immunohistochemistry markers in endometrial cancer with mismatch repair deficiency: a systematic review","volume":"14","author":"Favier A","year":"2022","unstructured":"Favier A, Varinot J, Uzan C, Duval A, Brocheriou I, Canlorbe G. The role of immunohistochemistry markers in endometrial cancer with mismatch repair deficiency: a systematic review. Cancers (Basel). 2022, 14:3783. 10.3390\/cancers14153783","journal-title":"Cancers (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17495","article-title":"Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status","volume":"9","author":"de Freitas D","year":"2023","unstructured":"de Freitas D, Aguiar FN, Anton C, de Almeida DC, Bacchi CE, Carvalho JP, Carvalho FM. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status. Heliyon. 2023, 9:e17495. 10.1016\/j.heliyon.2023.e17495","journal-title":"Heliyon"},{"key":"ref22","article-title":"Investigation of the relationship between immunohistochemical mismatch repair (MMR) protein expression and prognostic parameters in endometrial carcinomas","volume":"1","author":"Serin G","year":"2023","unstructured":"Serin G, Savas\u0327 P, O\u0308zdemir N, et al.. Investigation of the relationship between immunohistochemical mismatch repair (MMR) protein expression and prognostic parameters in endometrial carcinomas. Adv Obstet Gynaecol Res. 2023, 1:24-31.","journal-title":"Adv Obstet Gynaecol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/uog.23573","article-title":"Combination of Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer","volume":"58","author":"Eriksson LS","year":"2021","unstructured":"Eriksson LS, Nastic D, Lindqvist PG, Imboden S, J\u00e4rnbert-Pettersson H, Carlson JW, Epstein E. Combination of Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer. Ultrasound Obstet Gynecol. 2021, 58:457-68. 10.1002\/uog.23573","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051348","article-title":"Testing for Lynch syndrome in endometrial carcinoma: from universal to age-selective MLH1 methylation analysis","volume":"14","author":"Pasanen A","year":"2022","unstructured":"Pasanen A, Loukovaara M, Kaikkonen E, et al.. Testing for Lynch syndrome in endometrial carcinoma: from universal to age-selective MLH1 methylation analysis. Cancers (Basel). 2022, 14:1348. 10.3390\/cancers14051348","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen A","year":"2020","unstructured":"Pasanen A, Loukovaara M, B\u00fctzow R. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Mod Pathol. 2020, 33:1443-52. 10.1038\/s41379-020-0501-8","journal-title":"Mod Pathol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000001096","article-title":"Molecular classification of endometrial carcinoma: insights from a teaching hospital","volume":"44","author":"Saharti S","year":"2025","unstructured":"Saharti S, Altaf F. Molecular classification of endometrial carcinoma: insights from a teaching hospital. Int J Gynecol Pathol. 2025, 44:336-9. 10.1097\/PGP.0000000000001096","journal-title":"Int J Gynecol Pathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4436","article-title":"Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas","volume":"27","author":"Momeni-Boroujeni A","year":"2021","unstructured":"Momeni-Boroujeni A, Dahoud W, Vanderbilt CM, et al.. Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas. Clin Cancer Res. 2021, 27:2613-23. 10.1158\/1078-0432.CCR-20-4436","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004073","article-title":"Endometrial carcinosarcoma","volume":"33","author":"Bogani G","year":"2023","unstructured":"Bogani G, Ray-Coquard I, Concin N, et al.. Endometrial carcinosarcoma. Int J Gynecol Cancer. 2023, 33:147-74. 10.1136\/ijgc-2022-004073","journal-title":"Int J Gynecol Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-023-07005-9","article-title":"Relationship between molecular markers and lymphadenectomy and lymphovascular space invasion in endometrial cancer","volume":"308","author":"Bilir F","year":"2023","unstructured":"Bilir F, Ar\u0131oz DT, Ar\u0131kan SE, et al.. Relationship between molecular markers and lymphadenectomy and lymphovascular space invasion in endometrial cancer. Arch Gynecol Obstet. 2023, 308:941-6. 10.1007\/s00404-023-07005-9","journal-title":"Arch Gynecol Obstet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0266","article-title":"Adjuvant treatment for pole proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues","volume":"24","author":"Van Gool IC","year":"2018","unstructured":"Van Gool IC, Rayner E, Osse EM, et al.. Adjuvant treatment for pole proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues. Clin Cancer Res. 2018, 24:3197-203. 10.1158\/1078-0432.CCR-18-0266","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-021-06028-4","article-title":"Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer","volume":"303","author":"Raffone A","year":"2021","unstructured":"Raffone A, Travaglino A, Gabrielli O, et al.. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer. Arch Gynecol Obstet. 2021, 303:1393-400. 10.1007\/s00404-021-06028-4","journal-title":"Arch Gynecol Obstet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451843-correlation-of-histopathological-parameters-with-molecular-markers-in-carcinoma-endometrium","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:11:30Z","timestamp":1775034690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451843-correlation-of-histopathological-parameters-with-molecular-markers-in-carcinoma-endometrium"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.106256","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}